bluebird bio saw the highest growth of 0.99% in patent filings in April and 1.99% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.99% and grants by 0.99%. GlobalData’s DataBook provides a comprehensive analysis of bluebird bio’s patent filings and grants. Buy the databook here.
bluebird bio has been focused on protecting inventions in Israel(IL) with three publications in Q2 2024
The Israel(IL) Patent Office dominates the patent filings and grants with nearly 50% filings and 40% grants. The Israel(IL), European Patent Office(EPO), and United States(US) patent Office are among the top ten patent offices where bluebird bio is filings its patents. Among the top granted patent authorities, bluebird bio has 60% of its grants in United States(US) and 40% in Israel(IL).
Immatics could be the strongest competitor for bluebird bio
Patents related to cell & gene therapy and rare diseases lead bluebird bio's portfolio
bluebird bio has the highest number of patents in cell & gene therapy followed by, rare diseases. For cell & gene therapy no patents were filed and 50% of patents were granted in Q2 2024.
Leukemia related patents lead bluebird bio portfolio followed by sarcomas, and advanced malignancy
bluebird bio has highest number of patents in leukemia followed by sarcomas, advanced malignancy, lymphoma, and multiple myeloma (kahler disease).
For comprehensive analysis of bluebird bio's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.